On Thursday, Sage Therapeutics Inc. SAGE introduced that Biogen Inc BIIB had terminated its rights underneath the collaboration and license settlement with Sage, which was particular to the SAGE-324 program.
The businesses just lately introduced detrimental outcomes from the Section 2 KINETIC 2 Research of investigational SAGE-324 for the power therapy of important tremor (ET) and discontinued additional scientific growth of SAGE-324 in ET.
Important tremor is a neurological dysfunction that causes involuntary shaking or trembling in sure physique elements.
In July, the businesses introduced outcomes from the Section 2 KINETIC 2 dose-range examine of SAGE-324 (BIIB124) as a possible therapy for important tremor (ET).
The KINETIC 2 Research didn’t exhibit a statistically vital dose-response relationship in change from baseline to Day 91 primarily based on the first endpoint, The Important Tremor Score Evaluation Scale (TETRAS) Efficiency Subscale (PS) Merchandise 4 (higher limb) whole rating.
TETRAS is used to quantify the severity of tremors and their influence on day by day residing actions.
Given these outcomes, Sage and Biogen will shut the continued open-label security examine of SAGE-324 in ET and don’t plan to conduct additional scientific growth of SAGE-324 in ET.
Underneath the phrases of the collaboration and license settlement, the termination shall be efficient on February 17, 2025, and Sage will resume full possession of the SAGE-324 asset.
Sage plans to proceed to guage different potential indications, if any, for SAGE-324.
Sage and Biogen will proceed to companion on Zurzuvae (zuranolone), the primary and solely FDA-approved oral therapy for girls with postpartum despair.
Value Motion: On the final verify on Thursday, SAGE inventory was up 1.42% at $7.12, and BIIB inventory was up 1.77% at $192.42.
Learn Subsequent:
Market Information and Knowledge dropped at you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
